Telomerase inhibition as an adjuvant anticancer therapy: it is more than just a waiting game.
A telomere maintenance mechanism is essential for cancer cells to divide indefinitely. As telomerase maintains telomeres in the vast majority of human cancers, targeting tumor cells in patients with antitelomerase-based strategies is very appealing. However, as the complexities of telomere dynamics and telomerase regulation and function continue to unfold, translating this knowledge into well-designed clinical trials becomes daunting. Here, the authors discuss potential shortcomings for antitelomerase approaches and predict that inhibition of telomerase will be an effective targeted approach against cancer as a polytherapy in the adjuvant setting.